Ikena Oncology Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
IMA$3.81-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(49,234) | $(68,166) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 490 | 1,020 |
| Net accretion of discounts on marketable securities | (1,468) | (2,023) |
| Stock-based compensation expense | 5,295 | 7,632 |
| Non-cash operating lease expense | 2,051 | 1,714 |
| Loss on disposal of property and equipment | 99 | 5 |
| Impairment of right-of-use asset | — | 1,744 |
| Impairment of assets held for sale | 742 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 390 | 1,835 |
| Deposits and other assets | 2,390 | (1,824) |
| Accounts payable | (1,169) | (2,870) |
| Accrued expenses and other current liabilities | (2,484) | (7,660) |
| Operating lease liabilities | (3,217) | (2,087) |
| Deferred revenue | — | (9,160) |
| Other long-term liabilities | 111 | 97 |
| Net cash used in operating activities | (46,004) | (79,743) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | — | (414) |
| Proceeds from sale of property and equipment | 435 | — |
| Purchases of marketable securities | (88,298) | (90,052) |
| Proceeds from maturities of marketable securities | 60,460 | 154,610 |
| Amounts loaned under note receivable | (7,500) | — |
| Net cash provided by (used in) investing activities | (34,903) | 64,144 |
| Cash flows from financing activities: | ||
| Cash and cash equivalents acquired in connection with the acquisition of Pionyr, net of issuance costs paid | — | 40,030 |
| Cash consideration paid in connection with the acquisition of Pionyr | — | (944) |
| Proceeds from issuance of common stock for underwritten registered offering, net of offering costs | — | 37,421 |
| Repurchase of common stock | — | (663) |
| Proceeds from exercise of stock options | — | 136 |
| Net cash provided by financing activities | — | 75,980 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (80,907) | 60,381 |
| Cash, cash equivalents and restricted cash, beginning of period | 121,172 | 60,791 |
| Cash, cash equivalents and restricted cash, end of period | $40,265 | $121,172 |
| Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets: | ||
| Cash and cash equivalents | $39,393 | $119,894 |
| Restricted cash included in deposits and other assets | 872 | 1,278 |
| Cash, cash equivalents and restricted cash, end of period | $40,265 | $121,172 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.